Verition Fund Management
CTMX icon

Verition Fund Management’s CytomX Therapeutics CTMX Stock Holding History

Verition Fund Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-27,296
Closed -$43.7K – 2220
2022
Q4 		$43.7K Buy
+27,296
New +$40.4K ﹤0.01% 1894
2018
Q4 		– Sell
-13,998
Closed -$259K – 889
2018
Q3 		$259K Buy
+13,998
New +$319K 0.01% 1080

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Verition Fund Management's CTMX Position: Q1 2023 in Review

Verition Fund Management sold out of CytomX Therapeutics (CTMX) in Q1 2023, closing a stake of 27,296 shares — an estimated $43.7K sold.

Verition Fund Management first reported a position in CTMX in Q3 2018 and held it in 2 quarters. The position peaked at $259K in Q3 2018. 75 funds tracked by Wall St. Rank hold CTMX as of Q1 2023.

  • Verition Fund Management reported no remaining CytomX Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Verition Fund Management sold 27,296 CytomX Therapeutics shares in Q1 2023, an estimated $43.7K.
  • Verition Fund Management first reported a position in CytomX Therapeutics in Q3 2018 and held it in 2 quarters.
  • Verition Fund Management's CytomX Therapeutics position peaked at $259K in Q3 2018.
  • 75 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2023.

Based on Verition Fund Management's 13F filing for Q1 2023, filed 15 May 2023.